Angelini Ventures
Investment Details
Investor Type
Corporate VC
Asset Class Focus
Venture Capital
Stage Focus
Pre-Seed, Seed, Early Stage
Geographical Focus
United States, United Kingdom, Canada, Germany, Singapore, France, Italy, Denmark, Switzerland, Spain, Ireland, Austria, Netherlands, Portugal, Sweden, Belgium, Israel, Norway, Finland, Poland
Industries Focus
- HealthTech
- Life Sciences
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Medtech
- Biotechnology
- Infectious Diseases
- Consumer Health
- Therapeutics
- Genomics
- Immuno-Oncology
- Women's Health
- Cardiovascular
- Mental Health
- Neurotechnology
- Chronic Diseases
- Pediatrics
- Geriatrics
Investment Size:
1,500,000 to 3,000,000 USD
Investor Details Founded: 2022
Angelini Ventures is the corporate venture capital arm of Angelini Industries, focusing on early-stage investments in biotechnology, digital health, and life sciences sectors. Established in October 2022 with a €300 million capital commitment, the firm aims to disrupt traditional healthcare models by supporting innovative startups across Europe and North America. The company is headquartered in Rome, Italy, and operates globally with a team of professionals in cities including Milan, Turin, London, Singapore, Boston, Berlin, Copenhagen, Geneva, New York, Munich, and Basel.
The firm's investment strategy emphasizes brain health and consumer segments such as women, children, and the elderly. Angelini Ventures has already allocated approximately €125 million to startups developing solutions in biotechnology, medtech, and digital health. Notable investments include Argobio, a Paris-based biotech venture studio; Angelini Lumira Biosciences Fund, a North American fund investing in early-stage companies; and Pretzel Therapeutics, a Boston-based company specializing in mitochondrial therapeutics.
In November 2025, Angelini Ventures expanded its global presence by opening its first Asia office in Singapore. This office serves as a regional hub for biotech and healthtech innovation, housing the firm's Global Intelligence Hub and facilitating collaborations with key institutional partners and ecosystem leaders in the region. The expansion underscores Angelini Ventures' commitment to accelerating the growth of innovative ventures in healthcare on a global scale.
Requirements
- Innovative solutions in biotechnology, digital health, and life sciences
- Focus on brain health and consumer segments such as women, children, and the elderly
- Early-stage companies with potential to disrupt traditional healthcare models
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Argobio
- Angelini Lumira Biosciences Fund
- Pretzel Therapeutics
- Nuevocor
- Serenis
Claim this Investor
Are you an official representative of Angelini Ventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim